Shionogi & Co., Ltd. (SGIOF) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Osaka, 일본. 현재 CEO는 Isao Teshirogi.
SGIOF 을(를) 보유 IPO 날짜 2018-02-28, 4,955 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $18.59B.
Shionogi & Co., Ltd. is a Japanese pharmaceutical company founded in 1878 and headquartered in Osaka that engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company's marketed products include Fetroja for multidrug-resistant gram-negative bacterial infections, Xofluza for influenza, and Tivicay for HIV treatment. Shionogi maintains a substantial pipeline of drug candidates across multiple therapeutic areas including infectious diseases, oncology, central nervous system disorders, and rare diseases, with notable programs in obesity, depression, neuropathic pain, and COVID-19 treatments. The company also collaborates with leading academic institutions including Nagasaki University and the National Institute of Infectious Diseases on antimalarial drug development initiatives.
